Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2017

01-09-2017 | Research Article

Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer

Authors: K. Zhou, F. Wen, P. Zhang, J. Zhou, H. Chen, H. Zheng, Y. Yang, Q. Li

Published in: Clinical and Translational Oncology | Issue 9/2017

Login to get access

Abstract

Purpose

Second-line chemotherapy has been shown to benefit patients with advanced gastric cancer (AGC), extending the overall survival (OS) and progression-free survival (PFS). This study aimed to assess the efficacy and cost-effectiveness of second-line treatment for elderly patients with AGC.

Methods

Medical records and follow-up information of elderly patients (≥70 years) with AGC who received second-line chemotherapy were collected. A Markov model comprising three health states PFS, progressive disease and death was developed to simulate the process of AGC. Cost was calculated from the perspective of Chinese society. Sensitivity analyses were applied to explore the impact of essential variables.

Results

Forty-three elderly patients with AGC receiving second-line chemotherapy were included in our study. The median OS was 6.0 months (95% confidence interval (CI) 3.90–8.10) and PFS was 3.1 months (95% CI 1.38–4.82). No treatment-related death occurred. The most frequently drug-related grade 3/4 AEs were diarrhea (2.3%), leukopenia (16.3%) and nausea (7.0%). The incremental cost-effective ratio was $18,223.75/QALY for second-line chemotherapy versus BSC, which was below the threshold of 3× the per capita GDP of China, $23,970.00.

Conclusion

Second-line chemotherapy was an optimal strategy for elderly AGC patients in China from the efficacy and cost-effectiveness perspective.
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136(5):E359–86.CrossRefPubMed
2.
Ai-wen Wu, Ji Jia-fu, Yang Hong, Li Yan-ning, Li Shuang-xi, Zhang Lian-hai, et al. Long-term outcome of a large series of gastric cancer patients in China. Chin J Cancer Res. 2010;22(22):167–75.
3.
Zhao G, Ford ES, Ahluwalia IB, Li C, Mokdad AH. Prevalence and trends of receipt of cancer screenings among US women with diagnosed diabetes. J Gen Intern Med. 2008;24(2):270–5.CrossRefPubMedPubMedCentral
4.
Liu Jian, Sun Li-Ping, Gong Yue-Hua, Yuan Yuan. Risk factors of precancerous gastric lesions in a population at high risk of gastric cancer. Chin J Cancer Res. 2010;22(4):267–73.CrossRef
5.
Katherine D, Neugut Al. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354–62.CrossRef
6.
Kitamura K, Yamaguchi T, Taniguchi H, Hagiwara A, Yamane T, Sawai K, et al. Clinicopathological characteristics of gastric cancer in the elderly. Br J Cancer. 1996;73(6):798–802.CrossRefPubMedPubMedCentral
7.
Oohara T, Johjima Y, Yamamoto O, Tohma H, Kondo Y. Gastric cancer in patients above 70 years of age. World J Surg. 1984;8(3):315–20.CrossRefPubMed
8.
Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30(13):1513–8.CrossRefPubMed
9.
Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47(47):2306–14.CrossRefPubMed
10.
Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet. 2014;15(1):78–86.CrossRefPubMed
11.
Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 Study. J Clin Oncol. 2013;31(31):3935–43.CrossRefPubMed
12.
Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Mak. 1993;13(4):322–38.CrossRef
13.
Purmonen T, Martikainen JA, Soini EJ, Kataja V, Vuorinen RL, Kellokumpu-Lehtinen PL. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin Ther. 2008;30:382–92.CrossRefPubMed
14.
Shiroiwa T, Fukuda T, Shimozuma K. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer. 2011;105(9):1273–8.CrossRefPubMedPubMedCentral
15.
16.
Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31:4438–44.CrossRefPubMed
17.
Ohba A, Takashima A, Nishiuchi T, Honma Y, Iwasa S, Okita N, et al. Second-line chemotherapy with paclitaxel for elderly patients with advanced gastric cancer. J Clin Oncol. 2016;34:108 (meeting abstracts).CrossRef
18.
Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.CrossRefPubMed
19.
Catalano V, Bisonni R, Graziano F, Giordani P, Alessandroni P, Baldelli AM, et al. A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases. Gastric Cancer. 2013;16(3):411–9.CrossRefPubMed
20.
Chen XZ, Jiang K, Hu JK, Zhang B, Gou HF, Yang K, et al. Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China. World J Gastroenterol. 2008;14(17):2715–22.CrossRefPubMedPubMedCentral
21.
Glimelius B, Hoffman K, Graf W, Haglund U, Nyrén O, Påhlman L, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol Off J Eur Soc Med Oncol. 1995;6(3):267–74.CrossRef
Metadata
Title
Efficacy and cost-effectiveness of second-line chemotherapy in elderly patients with advanced gastric cancer
Authors
K. Zhou
F. Wen
P. Zhang
J. Zhou
H. Chen
H. Zheng
Y. Yang
Q. Li
Publication date
01-09-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 9/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1647-9

Other articles of this Issue 9/2017

Clinical and Translational Oncology 9/2017 Go to the issue

Research Article

Inflammation-based indexes and clinicopathologic features are strong predictive values of preoperative circulating tumor cell detection in gastric cancer patients

Research Article

Implementation of safeguards to improve patient safety in chemotherapy

Erratum

Erratum to: Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies

Special Article

The time has come for new models in febrile neutropenia: a practical demonstration of the inadequacy of the MASCC score

Research Article

The TNM 8 M1b and M1c classification for non-small cell lung cancer in a cohort of patients with brain metastases

Review Article

Role of TIM-3 in ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits